Graft Versus Host Disease
Recently Identified Biomarkers Found to Warn of Chronic Graft-vs-Host Disease in Marrow Transplant PatientsJuly 01, 2016
Researchers recently identified CXCL10, a protein that could act as a biomarker for chronic graft-versus-host disease (cGVHD), a long-term adverse effect that develops in some patients after undergoing blood and bone marrow transplant.
Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical TransplantationApril 25, 2016
Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.
A short-chain fatty acid made by bacteria in the gut could play an important role in GVHD after allogeneic bone marrow transplant in mice. In human patients who receive bone marrow transplants, GVHD can cause severe gut damage.
Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.
Rejection seen with high-expression allele recipient, low-expression allele donor in HLA-DPB1 mismatches
A new test can assist in the treatment of patients with graft-versus-host disease (GVHD), an often life-threatening complication of bone marrow and stem cell transplants.
A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.
A short course of cyclophosphamide can not only prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate need for the typical 6-month round of immune suppression medicines.
A simple questionnaire that rates breathing difficulties on a scale of 0 to 3 predicts survival in chronic graft-vs-host disease, according to a new study.
Adding bortezomib to standard preventive therapy for GVHD results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to research presented at the 2013 ASH Annual Meeting, in New Orleans.
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a new study from researchers.
The chemotherapy drug cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants through an immune system cell that evades the toxic effects of cyclophosphamide.
T cells overexpressing the TRAIL protein destroyed graft-versus-host disease caused by stem cell transplant for leukemia and other cancers.
Specially treated T cells infused into high-risk and relapsed leukemia patients can prolong survival after stem cell transplantation.
An experimental drug combination for preventing graft-versus-host disease was not significantly better than the standard regimen on key end points.
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
Among patients who receive either peripheral blood stem cells (PBMCs) or bone marrow from unrelated donors, the incidence of overall chronic graft-versus-host-disease (GVHD; 53%) is higher in those who received PBMCs than in those who received bone marrow stem cells (40%).
The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.
An HIV drug helped lower the risk of graft-versus-host disease in persons with blood cancer who had stem-cell transplants to rebuild bone marrow.
A regimen using minimal-intensity radiation therapy before bone marrow or stem cell transplantation may work for older patients who cannot tolerate stronger pretransplant treatment.
Scientists have improved a method for bone marrow transplantation from mismatched donors that would help restore the immune system quicker, according to findings presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|